within Pharmacolibrary.Drugs.ATC.D;

model D01AE23
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D01AE23</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Butenafine is a synthetic benzylamine antifungal agent primarily used topically for the treatment of superficial dermatophytoses, such as tinea corporis, tinea cruris, and tinea pedis. It inhibits the synthesis of ergosterol, an essential component of fungal cell membrane, leading to increased membrane permeability and cell death. Butenafine is approved for topical use in several countries and remains in use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for butenafine after topical (dermal) administration in healthy adults, as no published studies on systemic pharmacokinetics in humans are available. Parameters are extrapolated from topical pharmacology and animal studies.</p><h4>References</h4><ol><li><p>Singal, A (2008). Butenafine and superficial mycoses: current status. <i>Expert opinion on drug metabolism &amp; toxicology</i> 4(7) 999–1005. DOI:<a href=&quot;https://doi.org/10.1517/17425255.4.7.999&quot;>10.1517/17425255.4.7.999</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18624686/&quot;>https://pubmed.ncbi.nlm.nih.gov/18624686</a></p></li><li><p>Syed, TA, &amp; Maibach, HI (2000). Butenafine hydrochloride: for the treatment of interdigital tinea pedis. <i>Expert opinion on pharmacotherapy</i> 1(3) 467–473. DOI:<a href=&quot;https://doi.org/10.1517/14656566.1.3.467&quot;>10.1517/14656566.1.3.467</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11249531/&quot;>https://pubmed.ncbi.nlm.nih.gov/11249531</a></p></li><li><p>Mitra, A, et al., &amp; Meyer, TA (2016). Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butenafine hydrochloride (1%, w/w). <i>Regulatory toxicology and pharmacology : RTP</i> 82 14–19. DOI:<a href=&quot;https://doi.org/10.1016/j.yrtph.2016.11.008&quot;>10.1016/j.yrtph.2016.11.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27816671/&quot;>https://pubmed.ncbi.nlm.nih.gov/27816671</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D01AE23;
